On 15 July 2013, the FDA approved afatinib as a first-line treatment for patients with metastatic non-small-cell lung cancer whose tumours harbour exon 19 deletions or exon 21 (L858R) EGFR substitution mutations. We discuss three recent studies investigating afatinib in this molecular subset of patients.
Lung cancers with EGFR mutations are dependent on EGFR signalling for survi val and proliferation, making them highly sensitive to treatment with EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib or erlotinib. EGFR mutations were first described in 2004, 1 more than 5 years after these agents were introduced into the clinic. The official FDA approval of erlo tinib for the firstline treatment of patients with EGFR mutant nonsmallcell lung cancer (NSCLC) took another 9 years, in part because erlotinib and gefitinib were developed as inhibitors of wildtype EGFR; pharma ceutical companies had hoped that they would benefit all patients with NSCLC.
The development of erlotinib, a first generation reversible ATPcompetitive inhibitor of EGFR, reflects our evolving understanding of molecularly driven lung cancers. Initially, patients with adeno carcinoma, squamouscell carcinoma or largecell carcinoma were treated with either erlotinib alone or erlotinib with con current chemotherapy. Erlotinib received FDA approval in 2004 based on data from BR.21, a randomized trial comparing erlo tinib to placebo in patients with NSCLC that had disease progression on firstline treatment. 2 The differences in overall response rates (ORR) and progression free survival (PFS) were modest at best (9% versus 1% and 10 weeks versus 8 weeks, respectively). After EGFR mutations were identified, subsequent studies focused on this molecular subset of patients. 3, 4 In the EURTAC trial, erlotinib was compared with platinum doublet chemotherapy as firstline treatment for patients with EGFRmutant lung cancers, and erlotinib demonstrated a drama tic improvement in the ORR (58% versus 15%) and median PFS (10 months versus 5 months). 4 This study was the basis for the 'new' FDA indication on 14 May 2013, for erlotinib in patients with lung cancers harbouring EGFR exon 19 deletions and EGFR L858R substitutions.
Unfortunately, all patients who initially respond to treatment with EGFR TKIs will develop disease progression after a median of 12 months.
3 More than half of tumours biopsied following disease pro gression demonstrate an acquired second site mutation, EGFR T790M.
5 Afatinib, a 'secondgeneration' EGFR TKI, is an irreversible, covalentlybound inhibitor of EGFR that in preclinical studies was shown to be more potent than erlotinib against all forms of EGFR, including wildtype, exon 19 d eletion, L858R and T790M. Afatinib has been studied as both firstline treatment for patients with EGFR mutant lung cancers and as treatment in the EGFR TKI acquired resistance setting (Table 1) .
In LUXLung 3, 6,7 Sequist, Yang and col leagues compared afatinib 40 mg orally once daily with cisplatin plus pemetrexed as firstline treatment for patients with EGFRmutant lung adenocarcinomas. PFS was 11 months with afatinib versus 7 months with chemotherapy (P = 0.001) when includ ing all patients with EGFR mutations. When only patients with EGFR exon 19 deletions and EGFR L858 point mutations were studied, PFS for those treated with afatinib was 14 months. Response rates were more than double with afatinib compared with chemotherapy: 56% versus 23% (P = 0.001). Among the patientreported outcomes, time to deterioration for cough (hazard ratio [HR] 0.60, P = 0.007) and shortness of breath (HR 0.68, P = 0.015) were longer with afatinib. The adverse effects profiles for the two arms differed, with more fatigue and nausea noted with chemotherapy and more diarrhoea, sore mouth and dysphagia observed with afatinib. This study builds upon previous trials and demonstrates that afatinib is an effective firstline treatment for patients with EGFRmutant lung cancer.
To evaluate afatinib in patients with acquired resistance to EGFR TKI, in the LUXLung 4 trial, 8 Katakami and colleagues assessed the drug in Japanese patients with lung adenocarcinomas that had disease progression after being on erlotinib or gefi tinib for at least 12 weeks previously. EGFR mutation testing was performed on >90% of patient samples, with 73% identified as EGFR mutation positive. Five of 61 (8% 95% CI 3-18%) evaluable patients had a partial response, with a disease control rate of 66%. The median PFS was 4 months (95% CI 3-5 months), and the median overall survival was 19 months (95% CI 15 months to not reached). A similar study, LUX Lung 1, randomly assigned patients who had received prior chemotherapy and an EGFR TKI to afatinib (50 mg orally daily) or placebo; this study did not demon strate an overall survival benefit with afatinib.
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The results of LUXLung 4 and LUX Lung 1 suggest that singleagent afatinib has minimal efficacy in patients previously treated with erlotinib or gefitinib.
Acquired resistance to EGFR TKI therapy eventually occurs in all patients, and the exact mechanism of resistance could impact the effectiveness of treatment given in the acquired resistance setting. Biopsies at the time of acquired resistance were not required in LUXLung 4, but could have provided insights into the subset of patients that derived greater benefit from afatinib. www.nature.com/nrclinonc
NEWS & VIEWS
Possible reasons for a lack of efficacy of afa tinib in LUXLung 1 and LUXLung 4 could be that at lower doses, afatinib inhibits EGFR exon 19 deletions and EGFR L858R mutants preferentially to EGFR T790M, and the doses of drug required to overcome EGFR T790M might be unachievable in humans because of toxicity. Combination therapy of afatinib with the antiEGFR antibody, cetuximab, might provide a way forward in patients with acquired resistance to erlo tinib and gefitinib therapy, as a phase IB trial has shown promising activity of this c ombination with a 32% response rate.
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For metastatic lung cancer, both the side effect profile and efficacy must be weighed when considering treatment options for patients. The sideeffect profile of EGFR TKIs is distinct from c hemotherapyd iarrhoea, rash, dry skin, mucositis and nail changes are most commonly observed with TKIs. Dose reductions of afatinib (stand ard dose 40 mg orally daily) were required in 52% of patients in the LUX Lung 3 trial, and treatmentrelated adverse events of grade ≥3 occurred in 49% and 48% of patients receiving afatinib and chemo therapy, respectively. 6 In the OPTIMAL trial, 3 19% of patients required dose reduc tions of erlotinib (standard dose 150 mg orally daily), and treatmentrelated adverse events of grade ≥3 occurred in 17% of patients receiving erlotinib. In total, 8% of patients on afatinib in LUXLung 3 required drug discontinuation owing to a treatmentrelated adverse event, whereas no patients in the OPTIMAL trial required drug d iscontinuation of erlotinib.
With regards to efficacy, afatinib, erlo tinib or gefitinib have not been compared directly, although the median PFS noted in published studies seems to be similar: 11-14 months for afatinib, 8-13 months for erlotinib and 9-11 months for gefi tinib. Assuming the costs of each drug are relatively similar, the question remains as to which drug will become the firstline treat ment of choice for this patient population. A study comparing gefitinib to afatinib as firstline treatment for patients with meta static EGFRmutant lung cancer is currently ongoing (LUXLung 7, NCT01466660), but a study comparing erlotinib with afatinib is not yet underway. Until superiority of one agent is established, the milder adverse effect profile of erlotinib might result in its continued use in the USA and Europe as the firstline treatment of choice for patients with EGFRmutant lung cancers. 
